A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Issue 5 (17th September 2009)

• Record Type: Journal Article
• Authors: Svenungsson, Elisabet; Gustafsson, Johanna; Leonard, Dag; Sandling, Johanna; Gunnarsson, Iva; Nordmark, Gunnel; Jönsen, Andreas; Bengtsson, Anders A; Sturfelt, Gunnar; Rantapää-Dahlqvist, Solbritt; Elvin, Kerstin; Sundin, Ulf; Garnier, Sophie; Simard, Julia F; Sigurdsson, Snaevar; Padyukov, Leonid; Syvänen, Ann-Christine; Rönnblom, Lars
• Is Part Of: Annals of the rheumatic diseases. Volume 69:Issue 5(2010)
• Page Start: 834
• Page End: 840
• Publication Date: 2009-09-17
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2009.115535
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: To investigate whether the risk allele for systemic lupus erythematosus (SLE) in the signal transducer and activator of transcription factor 4 (STAT4) gene, defined by the single nucleotide polymorphism (SNP) rs10181656(G), is associated with vascular events and/or presence of prothrombotic anti-phospholipid antibodies (aPL) in patients with SLE. Methods: Two independent groups of unrelated patients with SLE of Swedish ethnicity (n=424 and 154) were genotyped, and occurrence of previous manifestations of ischaemic heart disease (IHD), ischaemic cerebrovascular disease (ICVD) and venous thromboembolic events (VTE) was tabulated. aPL values were measured by ELISA. Matched controls (n=492 and 194) were genotyped. Results: The STAT4 risk allele was more frequent in patients with SLE with previous arterial events (combined OR (ORc )=1.5, 95% CI 1.1 to 2.0) compared to patients without such events. The association was mainly attributable to an accumulation of the risk allele among patients with ICVD (ORc =2.3, CI 1.6 to 3.3). There was no association with IHD or VTE. The presence of two or more aPLs was associated with the risk allele (ORc =1.6, 95% CI 1.2 to 2.0). In multivariable-adjusted logistic regression analyses treatment for hypertension, at least one STAT4 risk allele, older age, IgG anti-cardiolipin antibodies and longer SLE duration remained independently associated with previous ICVD (p≤0.02 for all). Conclusion: Patients with SLE with the STAT4 risk allele had a strikingly increased risk of ICVD, comparable in magnitude to that of hypertension. The results imply that a genetic predisposition is an important and previously unrecognised risk factor for ICVD in SLE, and that aPLs may be one underlying mechanism.